CJC-1295 and Ipamorelin are two growth-hormone secretagogues that are often combined — but they work through different receptors. This guide explains how each one differs and why they’re paired. Both are research-use-only compounds — not approved for human use.
- CJC-1295: a GHRH analogue acting on the GHRH receptor.
- Ipamorelin: a GHRP-class peptide acting on the ghrelin receptor (GHS-R1a).
- Different pathways: two distinct routes to the same downstream signal.
- Status: not FDA-approved; research use only.
Side-by-side
| CJC-1295 | Ipamorelin | |
|---|---|---|
| Class | GHRH analogue | GHRP / ghrelin-receptor agonist |
| Receptor | GHRH receptor | GHS-R1a (ghrelin) |
| Noted for | Sustained GHRH-pathway signaling | Selective action with minimal off-target effects |
| Role in the pair | The GHRH side | The ghrelin side |
How they differ
The body regulates growth-hormone release through two main inputs: GHRH and ghrelin. CJC-1295 mimics GHRH, while Ipamorelin acts on the ghrelin (GHS-R1a) receptor. They are not interchangeable — they engage separate pathways, which is exactly why they’re studied as a pair.
Why they’re combined
Because the two receptors are distinct, activating both is of mechanistic interest in secretagogue research. That’s the basis of the CJC-1295 / Ipamorelin blend. For the broader category, see Growth Hormone Secretagogues Explained and the single-peptide analogue Tesamorelin.
Storage & handling
Both are supplied lyophilized. Keep cold and dark, reconstitute only when needed for research, and limit freeze–thaw cycles. See how to reconstitute lyophilized peptides.
Research status
CJC-1295 and Ipamorelin are not approved by the FDA for human use; the available evidence is preclinical. Treat both strictly as research compounds.
Explore the research-grade CJC-1295 / Ipamorelin blend
Lab-tested, with third-party purity verification.